Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Alcoholism

In brief

The purpose of this study is to determine whether perampanel alters the response to alcohol for heavy drinkers. It is hypothesized that perampanel will reduce the rewarding and reinforcing properties of alcohol in the laboratory setting.

Key facts

Study ID

NCT02120365

Run by

Virginia Commonwealth University

People needed

22

Starts

2019-06-01

Expected to finish

2022-02-16

Last updated by the study team

2023-08-18

Who can join

Age: 21 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• males and females
• between the ages of 21 and 55 years;
• Nontreatment-seeking Heavy Drinkers (NTSHDs)as defined above, and must have had at least 5 Standard Drinks (SD) in one day on at least some occasions in the past and been able to tolerate it without an adverse reaction
• generally medically and neurologically healthy on the basis of history, physical examination, Electrocardiogram, screening laboratory results (Complete Blood Count w/ differential, Thyroid Stimulating Hormone, Free-T4, Aspartate Transferase, Alanine Transferase, Gamma-Glutamyl Transferase, Blood Urea Nitrogen, creatinine, electrolytes, urinalysis, beta-Human Chorionic Gonadotropin). Individuals with Liver Function Tests (LFT) that are no more than 3 times above the normal levels will be included;
• women with a negative pregnancy test and not nursing, must be regularly using birth control
• negative breath alcohol at screening and on each test day;
• not taking any psychoactive medication or opioids (in past 30-days);
• are non-treatment seeking.

You may not qualify if…

• they need detoxification determined by a Clinical Institute Withdrawal Assessment (CIWA) score of >8 or have had a history of alcohol detoxification in the past;
• have been in treatment for an alcohol problem within the last 6 months, or if the severity of their alcohol problem based on the research physician's assessment warrants definitive treatment;
• meet criteria for Diagnostic Statistical Manual (DSM) -IV psychiatric and substance use disorder diagnosis (other than alcohol abuse/dependence, cannabis abuse/dependence and nicotine dependence; those diagnoses will be allowed; participants can be either smokers up to 1 pack per day or non-smokers) based on history and psychiatric evaluation that includes a structured diagnostic interview (Structured Clinical Interview for DSM-IV Axis I Disorders: SCID)
• unwillingness to remain alcohol-free 12 hours prior to test days;
• have a significant ongoing serious medical condition such as Diabetes Mellitus, liver disease (see above LFT guideline), renal disease (as evidenced by serum creatinine above our laboratory's reference limit of 1.7 mg/dL, or have a history of adverse reaction to IV placement/blood draw

Where it is running

• University of Connecticut — Farmington, Connecticut, United States
• Yale New Haven Hospital Research Unit — New Haven, Connecticut, United States
• West Haven Veterans Affairs — West Haven, Connecticut, United States
• Albert Arias — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.